drugset / Trial / NCT03611946
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a phase 1 double-blind, placebo controlled trial designed to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection.
Timeline
- Start
- 2018-07-06
- Primary completion
- 2022-03-18
- Completion
- 2022-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rZIKV/D4Δ30-713 | Unknown | 1000 unknown | Subcutaneous |
| Subject | rZIKV/D4Δ30-713 | Unknown | 10000 unknown | Subcutaneous |